Sodium‐glucose co‐transporter‐2 inhibitor therapy and unmasking of JAK2 ‐mutated myeloproliferative neoplasm: A Mayo Clinic series of nine consecutive cases
American Journal of Hematology · 2023-10 · 98 (10)
DOI: 10.1002/ajh.27034 ↗Kurz gefasst
Leserbrief in der Zeitschrift American Journal of Hematology, online erschienen am 20.07.2023. Verfasst von Naseema Gangat und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Bone Marrow Neoplasms, Symporters. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Hematopathology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Naseema Gangat, Ayalew Tefferi
Zitieren
APA
Gangat, N., Alkhateeb, H., Reichard, K., & Tefferi, A. (2023). Sodium‐glucose co‐transporter‐2 inhibitor therapy and unmasking of JAK2 ‐mutated myeloproliferative neoplasm: A Mayo Clinic series of nine consecutive cases. American Journal of Hematology, 98(10). https://doi.org/10.1002/ajh.27034
Vancouver
Gangat N, Alkhateeb H, Reichard K, Tefferi A. Sodium‐glucose co‐transporter‐2 inhibitor therapy and unmasking of JAK2 ‐mutated myeloproliferative neoplasm: A Mayo Clinic series of nine consecutive cases. American Journal of Hematology. 2023;98(10). doi:10.1002/ajh.27034
BibTeX
@article{Gangat2023,
author = {Gangat, Naseema and Alkhateeb, Hassan and Reichard, Kaaren and Tefferi, Ayalew},
title = {Sodium‐glucose co‐transporter‐2 inhibitor therapy and unmasking of JAK2 ‐mutated myeloproliferative neoplasm: A Mayo Clinic series of nine consecutive cases},
journal = {American Journal of Hematology},
year = {2023},
volume = {98},
number = {10},
doi = {10.1002/ajh.27034}
}
EUVIMED